Emerging Biomarkers in Acute Coronary Syndrome

Authors

  • Emmanuel Peter Mushi Tandabui Institute of Health Science and Technology, Mwanza, Tanzania Author

DOI:

https://doi.org/10.62046/60aqkk14

Keywords:

Acute coronary syndrome; Cardiac biomarkers; Troponin; Copeptin; Heart-type fatty acid-binding protein; Precision cardiology.

Abstract

Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide despite significant advances in cardiovascular diagnosis and treatment. Early recognition of myocardial ischemia and rapid risk stratification are essential for improving clinical outcomes. Cardiac troponins remain the gold standard biomarkers for diagnosing myocardial injury; however, they have limitations in detecting very early ischemia and predicting long-term prognosis. Recent research has identified several novel biomarkers reflecting myocardial injury, inflammation, plaque instability, thrombosis, endothelial dysfunction, oxidative stress, and cardiac remodeling. Biomarkers such as copeptin, heart-type fatty acid-binding protein (H-FABP), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity-2 (sST2), galectin-3, microRNAs, and circulating extracellular vesicles have shown promising diagnostic and prognostic value. Contemporary strategies increasingly combine multiple biomarkers with clinical assessment, electrocardiography, and cardiac imaging to improve early diagnosis and personalized management. This review summarizes current evidence regarding established and emerging biomarkers in acute coronary syndrome and discusses their potential clinical applications.

Downloads

Download data is not yet available.

Downloads

Published

2026-06-28

Issue

Section

Articles

How to Cite

Emerging Biomarkers in Acute Coronary Syndrome. (2026). E-Journal of Medical and Pharmaceutical Science, 2(2), 7-13. https://doi.org/10.62046/60aqkk14

Similar Articles

You may also start an advanced similarity search for this article.